Clinical trials: open to volunteers, in United Kingdom
Multiple Myeloma
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult…
- Trial name
- NCT06953960
- Testing
- Surzetoclax, Daratumumab, Dexamethasone
- Where
- 50 sites in United States, Australia and 10 more
- Volunteers
- 325 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study…
- Trial name
- NCT07003425
- Testing
- APG777
- Where
- 79 sites in United States, Canada and 7 more
- Volunteers
- 350 people
- Sponsor
- Apogee Therapeutics, Inc.
Glaucoma
A Study Evaluating the Safety and Efficacy of MINIject S+ in Subjects With Open Angle Glaucoma
This is a prospective, multi-center, international, cohort expansion study. Part 1 will be conducted in subjects with open angle glaucoma to identify the best insertion tool for MINIject S+.
- Trial name
- STAR VII (NCT07009236)
- Testing
- MIGS
- Where
- 5 sites in Honduras, United Kingdom
- Volunteers
- 60 people
- Sponsor
- iSTAR Medical
Ulcerative Colitis
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- MIGHTY (NCT07071519)
- Testing
- Risankizumab
- Where
- 72 sites in United States, Belgium and 14 more
- Volunteers
- 120 people
- Sponsor
- AbbVie
Pre-eclampsia
Oxford Luteal Dysfunction and Placental Insufficiency Study
High blood pressure (BP) affects approximately 1 in 10 pregnancies. About half of women with high blood pressure in pregnancy develop a serious complication called preeclampsia, which kills over 70,000 women and 500,000 babies…
- Trial name
- OxLuPIn (NCT07072052)
- Testing
- No intervention planned
- Where
- United Kingdom
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Breast Cancer, Axillary Lymph Nodes Dissection
Audit of Targeted Sentinel Node Biopsy (TSNB) in Patients With Limited Nodal Disease Undergoing Primary Surgery
Axillary ultrasound scan (AUS) is routinely employed in the UK for preoperative axillary staging and can diagnose approximately 50 - 80% of node positive patients when combined with percutaneous needle biopsy techniques (either…
- Conditions
- Breast Cancer, Axillary Lymph Nodes Dissection, Axillary Metastases, Sentinel Lymph Node Biopsy (SLNB)
- Trial name
- NodeSMART (NCT07085442)
- Testing
- Targeted Sentinel Node Biopsy (TSNB)
- Where
- 14 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- University Hospitals of Derby and Burton NHS Foundation Trust
Non-small Cell Lung Cancer
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well…
- Trial name
- NCT07111520
- Testing
- BNT326, Pumitamig
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 880 people
- Sponsor
- BioNTech SE
Metastatic Prostate Cancer
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.
- Trial name
- SEACLIFF (NCT07181161)
- Testing
- AZD0516, AZD9574
- Where
- 52 sites in United States, Brazil and 8 more
- Volunteers
- 283 people
- Sponsor
- AstraZeneca
Overactive Bladder
Tensi+ European Post-Market Clinical Follow-Up
Tensi+ (Stimuli Technology, Boulogne Billancourt, France) is a newly released, medical transcutaneous-posterior tibial nerve stimulation (TC-pTNS) device marketed for overactive bladder (OAB) management.
- Trial name
- NCT07205445
- Testing
- Tensi+
- Where
- 17 sites in France, Italy and 1 more
- Volunteers
- 500 people
- Sponsor
- Stimuli Technology
Prosthetic-joint Infection
Evaluation of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Knee Arthroplasty
The goal of this clinical trial is to evaluate whether the investigational drug PLG0206 can help reduce recurrence of infection in adults who have undergone total knee replacement and are receiving a DAIR (Debridement…
- Trial name
- RETAIN (NCT07214311)
- Testing
- PLG0206
- Where
- 21 sites in United States, United Kingdom
- Volunteers
- 240 people
- Sponsor
- Peptilogics
Type 2 Diabetes, Appetite Regulation
GLycaemic Outcomes With Whey Protein in ageING
The goal of this placebo-controlled, partial crossover design study is to identify the impact of consuming whey protein before meals on free-living glucose control in older adults living with type 2 diabetes.
- Conditions
- Type 2 Diabetes, Appetite Regulation, Whey Protein, Ageing and Geriatric Health
- Trial name
- GLOWING (NCT07285811)
- Testing
- Glycaemic control with whey protein, Glycaemic control with different doses of whey protein
- Where
- 2 sites in United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Birmingham
Peripheral Artery Disease (PAD)
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
This study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become…
- Trial name
- ROXI-PALISADE (NCT07318610)
- Testing
- REGN7508, REGN9933, Rivaroxaban
- Where
- 29 sites in United States, United Kingdom
- Volunteers
- 7,050 people
- Sponsor
- Regeneron Pharmaceuticals
Moderate to Severe Chronic Obstructive Pulmonary Disease
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD.
- Trial name
- COPD (NCT07363694)
- Testing
- PF-07275315 dose 1, PF-07275315-dose 2, PF-07275315-dose 3
- Where
- 189 sites in United States, Argentina and 16 more
- Volunteers
- 1,156 people
- Sponsor
- Pfizer
Achondroplasia
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
This is a multicenter, multinational, randomized, active-controlled, operationally seamless Phase 2/3 study of BMN 333 in treatment-naïve pediatric participants with achondroplasia (ACH).
- Trial name
- ASPEN (NCT07441876)
- Testing
- BMN 333, Vosoritide Injection [Voxzogo]
- Where
- 28 sites in United States, Australia and 7 more
- Volunteers
- 160 people
- Sponsor
- BioMarin Pharmaceutical
Muscle-invasive Bladder Cancer
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
People with a type of bladder cancer called muscle-invasive bladder cancer have cancer that has spread into the muscle wall of the bladder.
- Trial name
- NCT07475806
- Testing
- Enfortumab Vedotin, Pembrolizumab
- Where
- 66 sites in United States, Australia and 10 more
- Volunteers
- 240 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Autosomal Dominant RYR1-Related Myopathy
A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy
This study is testing a medicine called surlorian in adults who have a genetic muscle condition known as autosomal dominant RYR1-related myopathy (RYR1-RM).
- Trial name
- NCT07560020
- Testing
- Surlorian
- Where
- 9 sites in France, Germany and 3 more
- Volunteers
- 28 people
- Sponsor
- RyCarma Therapeutics, Inc.
Mesothelioma, Pancreatic Cancer
A 2-part Phase 1/2 Open-label Trial on ODM-212
An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)
- Conditions
- Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
- Trial name
- TEADCO (NCT07563738)
- Testing
- ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel
- Where
- 23 sites in United States, Denmark and 5 more
- Volunteers
- 229 people
- Sponsor
- Orion Corporation, Orion Pharma
End-stage Liver Disease (ESLD), Acute Liver Failure
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
Machine perfusion (MP) has become routine clinical practice in liver transplantation. However, as the field has matured, direct randomized comparisons between distinct MP modalities have become increasingly impractical, given…
- Conditions
- End-stage Liver Disease (ESLD), Acute Liver Failure, Liver Cirrhosis, Liver Transplantation
- Trial name
- REFRAME-MP (NCT07585890)
- Testing
- Endischemic hypothermic oxygenated machine perfusion (any device), Endischemic (back-to-base) normothermic machine perfusion (any device), Continuous (device-to-donor) normothermic machine perfusion (any device)
- Where
- 37 sites in Austria, Belgium and 8 more
- Volunteers
- 10,000 people
- Sponsor
- University Medical Center Groningen
Rhinovirus Infection
Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD
Compare the safety and efficacy of two different oral vapendavir doses with placebo in order to determine the appropriate dose of vapendavir to reduce the severity and/or duration of respiratory symptoms associated with RV…
- Trial name
- Cardinal COPD (NCT07610395)
- Testing
- VPV 1000 mg, VPV 500 mg
- Where
- 46 sites in United States, United Kingdom
- Volunteers
- 180 people
- Sponsor
- Altesa Biosciences, Inc.
Type 2 Diabetes Mellitus
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable…
- Trial name
- Eluminate-2 (NCT07662213)
- Testing
- Elecoglipron, Semaglutide
- Where
- 210 sites in United States, Argentina and 13 more
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca